FidoCure^® Veterinary Team Blog

Precision medicine revolutionizes cancer care by tailoring treatments to each patient's tumor, but major roadblocks remain. These top articles dive into the key challenges holding personalized oncology back and emerging solutions companies like FidoCure are exploring. You'll find insights on innovative clinical trial designs, cutting-edge technologies enabling more precise therapies, and even how studying cancer in pet dogs could accelerate new targeted drug development for both human and veterinary medicine. 

Transitional cell carcinoma (TCC) is the most common tumor affecting canine urinary bladders. It is highly invasive, can obstruct urinary outflow, and has a moderate metastasis rate in areas like lymph nodes and lungs. Several factors increase TCC risk, including older flea products, lawn chemicals, obesity, being female, and certain breeds like Scottish Terriers and Shetland Sheepdogs. Treatment typically involves radiation therapy and chemotherapy rather than surgery due to the tumor's invasive nature and location. Furthermore, TCC can be targeted with precision therapies enabled by FidoCure such as trametinib and lapatinib. 

On World Vet Day, we wanted to express our heartfelt gratitude to all our veterinarians and vet techs who work with our dogs. In recognition, we asked FidoCure pet parents to nominate their vets and tell us why  they've made such an immense impact on the lives of their dogs.

At the heart of veterinary science lies a deep compassion for the well-being of our beloved animal companions. This is where FidoCure can make a profound impact on the quality of life of your pet battling cancer by offering hope with targeted therapy to thousands of dogs through genomic sequencing and AI-driven data analysis of cancer mutations. 

We are thrilled to share with you an incredible milestone in our journey to revolutionize canine cancer treatment. Thanks to your unwavering support and dedication, we have now enrolled over 5,000 dogs in the FidoCure platform! This achievement is a testament to the trust you have placed in our innovative approach and the positive impact we are making together in the lives of dogs and their families.

Leading Animal Health Expert Dr. Fabian Kausche Joins FidoCure Advisory Board

FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024 

Our study in Nature's Scientific Reports was the 17th most downloaded cancer paper in 2023!

History and Initial Treatment

Pixelle, a 13 year old Shih Tzu, started her long cancer journey in June of 2020 when she was diagnosed with a left-sided adrenal mass after undergoing a thorough workup for vomiting, polyuria/polydipsia, and intermittent urinary incontinence. A pheochromocytoma was ruled out as a low-dose dexamethasone suppression test was consistent with Cushing’s Disease (cortisol secreting tumor).